Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer
CONCLUSION: Our results suggest that irinotecan monotherapy can be a useful alternative treatment option in the third-line setting for patients with SCLC.PMID:34847814 | DOI:10.1177/0300891620974762 (Source: Tumori)
Source: Tumori - December 1, 2021 Category: Cancer & Oncology Authors: Zenta Seto Naoki Takata Nozomu Murayama Kotaro Tokui Seisuke Okazawa Kenta Kambara Shingo Imanishi Toshiro Miwa Ryuji Hayashi Shoko Matsui Minehiko Inomata Source Type: research

Italian pediatric and adult oncology communities join forces for a national project dedicated to adolescents and young adults with cancer
We describe the development of an Italian national project dedicated to adolescents and young adults with cancer.PMID:34841968 | DOI:10.1177/03008916211058790 (Source: Tumori)
Source: Tumori - November 29, 2021 Category: Cancer & Oncology Authors: Andrea Ferrari Paola Quarello Maurizio Mascarin Giuseppe Luigi Banna Angela Toss Giovanna Sironi Marco Zecca Saverio Cinieri Fedro Alessandro Peccatori Source Type: research

"Based on a true story" podcast: a journey into the world of young patients with cancer
This article describes a creative project undertaken by a group of adolescent and young adult patients with cancer as part of the Milan's Youth Project, a scheme dedicated to young patients with cancer with the dual aim of optimizing medical aspects of their care and promoting a holistic approach to their needs. The project was based on audio recordings and focused on the theme of "the journey," such as a holiday or an adventure, or as a metaphor of the cancer experience. The podcast installments were published on the main streaming platforms. Talking about their disease and how they feel is of importance for you...
Source: Tumori - November 29, 2021 Category: Cancer & Oncology Authors: Andrea Ferrari Matteo Silva Gianfelice Facchetti Alice Patriccioli Paolo Grampa Michela Casanova Virginia Livellara Stefano Signoroni Carlo Alfredo Clerici Maura Massimino Source Type: research

Italian pediatric and adult oncology communities join forces for a national project dedicated to adolescents and young adults with cancer
We describe the development of an Italian national project dedicated to adolescents and young adults with cancer.PMID:34841968 | DOI:10.1177/03008916211058790 (Source: Tumori)
Source: Tumori - November 29, 2021 Category: Cancer & Oncology Authors: Andrea Ferrari Paola Quarello Maurizio Mascarin Giuseppe Luigi Banna Angela Toss Giovanna Sironi Marco Zecca Saverio Cinieri Fedro Alessandro Peccatori Source Type: research

"Based on a true story" podcast: a journey into the world of young patients with cancer
This article describes a creative project undertaken by a group of adolescent and young adult patients with cancer as part of the Milan's Youth Project, a scheme dedicated to young patients with cancer with the dual aim of optimizing medical aspects of their care and promoting a holistic approach to their needs. The project was based on audio recordings and focused on the theme of "the journey," such as a holiday or an adventure, or as a metaphor of the cancer experience. The podcast installments were published on the main streaming platforms. Talking about their disease and how they feel is of importance for you...
Source: Tumori - November 29, 2021 Category: Cancer & Oncology Authors: Andrea Ferrari Matteo Silva Gianfelice Facchetti Alice Patriccioli Paolo Grampa Michela Casanova Virginia Livellara Stefano Signoroni Carlo Alfredo Clerici Maura Massimino Source Type: research

Risk factors for primary site necrosis after definitive concurrent chemoradiotherapy in head and neck cancer
Tumori. 2021 Nov 22:3008916211059852. doi: 10.1177/03008916211059852. Online ahead of print.ABSTRACTOBJECTIVE: To identify risk factors of primary site necrosis (PSN) after definitive concurrent chemoradiation therapy (CCRT) in patients with nonoral cavity head and neck cancer (HNC).METHODS: We retrospectively reviewed the records of 256 patients treated with CCRT for HNC during 2010-2018. Patient-related (age, sex, history of smoking, hypertension, diabetes mellitus, serum hemoglobin and albumin), tumor-related (tumor site, American Joint Committee on Cancer stage), and treatment-related (induction chemotherapy, maximum p...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Donghyun Kim Yongkan Ki Wontaek Kim Dahl Park Jihyeon Joo Hosang Jeon Kyeonghyo Lee Jiho Nam Source Type: research

Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility?
Tumori. 2021 Nov 22:3008916211061604. doi: 10.1177/03008916211061604. Online ahead of print.ABSTRACTIn urothelial cancer of the bladder, the introduction of immunotherapy with immune checkpoint inhibitors represents progress in the management of the disease's early and advanced stages. In particular, recent studies have implemented these drugs in the neoadjuvant and adjuvant phases to treat muscle-invasive bladder cancer. In some studies, patients received neoadjuvant immune checkpoint inhibitors alone (PURE and ABACUS) to treat muscle invasive bladder cancer, whereas other studies provided this therapy to cisplatin-inelig...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Fausto Petrelli Gianluca Perego Ivano Vavassori Andrea Luciani Source Type: research

Risk factors for primary site necrosis after definitive concurrent chemoradiotherapy in head and neck cancer
Tumori. 2021 Nov 22:3008916211059852. doi: 10.1177/03008916211059852. Online ahead of print.ABSTRACTOBJECTIVE: To identify risk factors of primary site necrosis (PSN) after definitive concurrent chemoradiation therapy (CCRT) in patients with nonoral cavity head and neck cancer (HNC).METHODS: We retrospectively reviewed the records of 256 patients treated with CCRT for HNC during 2010-2018. Patient-related (age, sex, history of smoking, hypertension, diabetes mellitus, serum hemoglobin and albumin), tumor-related (tumor site, American Joint Committee on Cancer stage), and treatment-related (induction chemotherapy, maximum p...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Donghyun Kim Yongkan Ki Wontaek Kim Dahl Park Jihyeon Joo Hosang Jeon Kyeonghyo Lee Jiho Nam Source Type: research

Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility?
Tumori. 2021 Nov 22:3008916211061604. doi: 10.1177/03008916211061604. Online ahead of print.ABSTRACTIn urothelial cancer of the bladder, the introduction of immunotherapy with immune checkpoint inhibitors represents progress in the management of the disease's early and advanced stages. In particular, recent studies have implemented these drugs in the neoadjuvant and adjuvant phases to treat muscle-invasive bladder cancer. In some studies, patients received neoadjuvant immune checkpoint inhibitors alone (PURE and ABACUS) to treat muscle invasive bladder cancer, whereas other studies provided this therapy to cisplatin-inelig...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Fausto Petrelli Gianluca Perego Ivano Vavassori Andrea Luciani Source Type: research

Risk factors for primary site necrosis after definitive concurrent chemoradiotherapy in head and neck cancer
Tumori. 2021 Nov 22:3008916211059852. doi: 10.1177/03008916211059852. Online ahead of print.ABSTRACTOBJECTIVE: To identify risk factors of primary site necrosis (PSN) after definitive concurrent chemoradiation therapy (CCRT) in patients with nonoral cavity head and neck cancer (HNC).METHODS: We retrospectively reviewed the records of 256 patients treated with CCRT for HNC during 2010-2018. Patient-related (age, sex, history of smoking, hypertension, diabetes mellitus, serum hemoglobin and albumin), tumor-related (tumor site, American Joint Committee on Cancer stage), and treatment-related (induction chemotherapy, maximum p...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Donghyun Kim Yongkan Ki Wontaek Kim Dahl Park Jihyeon Joo Hosang Jeon Kyeonghyo Lee Jiho Nam Source Type: research

Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility?
Tumori. 2021 Nov 22:3008916211061604. doi: 10.1177/03008916211061604. Online ahead of print.ABSTRACTIn urothelial cancer of the bladder, the introduction of immunotherapy with immune checkpoint inhibitors represents progress in the management of the disease's early and advanced stages. In particular, recent studies have implemented these drugs in the neoadjuvant and adjuvant phases to treat muscle-invasive bladder cancer. In some studies, patients received neoadjuvant immune checkpoint inhibitors alone (PURE and ABACUS) to treat muscle invasive bladder cancer, whereas other studies provided this therapy to cisplatin-inelig...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Fausto Petrelli Gianluca Perego Ivano Vavassori Andrea Luciani Source Type: research

Risk factors for primary site necrosis after definitive concurrent chemoradiotherapy in head and neck cancer
Tumori. 2021 Nov 22:3008916211059852. doi: 10.1177/03008916211059852. Online ahead of print.ABSTRACTOBJECTIVE: To identify risk factors of primary site necrosis (PSN) after definitive concurrent chemoradiation therapy (CCRT) in patients with nonoral cavity head and neck cancer (HNC).METHODS: We retrospectively reviewed the records of 256 patients treated with CCRT for HNC during 2010-2018. Patient-related (age, sex, history of smoking, hypertension, diabetes mellitus, serum hemoglobin and albumin), tumor-related (tumor site, American Joint Committee on Cancer stage), and treatment-related (induction chemotherapy, maximum p...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Donghyun Kim Yongkan Ki Wontaek Kim Dahl Park Jihyeon Joo Hosang Jeon Kyeonghyo Lee Jiho Nam Source Type: research

Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility?
Tumori. 2021 Nov 22:3008916211061604. doi: 10.1177/03008916211061604. Online ahead of print.ABSTRACTIn urothelial cancer of the bladder, the introduction of immunotherapy with immune checkpoint inhibitors represents progress in the management of the disease's early and advanced stages. In particular, recent studies have implemented these drugs in the neoadjuvant and adjuvant phases to treat muscle-invasive bladder cancer. In some studies, patients received neoadjuvant immune checkpoint inhibitors alone (PURE and ABACUS) to treat muscle invasive bladder cancer, whereas other studies provided this therapy to cisplatin-inelig...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Fausto Petrelli Gianluca Perego Ivano Vavassori Andrea Luciani Source Type: research

Risk factors for primary site necrosis after definitive concurrent chemoradiotherapy in head and neck cancer
Tumori. 2021 Nov 22:3008916211059852. doi: 10.1177/03008916211059852. Online ahead of print.ABSTRACTOBJECTIVE: To identify risk factors of primary site necrosis (PSN) after definitive concurrent chemoradiation therapy (CCRT) in patients with nonoral cavity head and neck cancer (HNC).METHODS: We retrospectively reviewed the records of 256 patients treated with CCRT for HNC during 2010-2018. Patient-related (age, sex, history of smoking, hypertension, diabetes mellitus, serum hemoglobin and albumin), tumor-related (tumor site, American Joint Committee on Cancer stage), and treatment-related (induction chemotherapy, maximum p...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Donghyun Kim Yongkan Ki Wontaek Kim Dahl Park Jihyeon Joo Hosang Jeon Kyeonghyo Lee Jiho Nam Source Type: research

Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility?
Tumori. 2021 Nov 22:3008916211061604. doi: 10.1177/03008916211061604. Online ahead of print.ABSTRACTIn urothelial cancer of the bladder, the introduction of immunotherapy with immune checkpoint inhibitors represents progress in the management of the disease's early and advanced stages. In particular, recent studies have implemented these drugs in the neoadjuvant and adjuvant phases to treat muscle-invasive bladder cancer. In some studies, patients received neoadjuvant immune checkpoint inhibitors alone (PURE and ABACUS) to treat muscle invasive bladder cancer, whereas other studies provided this therapy to cisplatin-inelig...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Fausto Petrelli Gianluca Perego Ivano Vavassori Andrea Luciani Source Type: research

Risk factors for primary site necrosis after definitive concurrent chemoradiotherapy in head and neck cancer
Tumori. 2021 Nov 22:3008916211059852. doi: 10.1177/03008916211059852. Online ahead of print.ABSTRACTOBJECTIVE: To identify risk factors of primary site necrosis (PSN) after definitive concurrent chemoradiation therapy (CCRT) in patients with nonoral cavity head and neck cancer (HNC).METHODS: We retrospectively reviewed the records of 256 patients treated with CCRT for HNC during 2010-2018. Patient-related (age, sex, history of smoking, hypertension, diabetes mellitus, serum hemoglobin and albumin), tumor-related (tumor site, American Joint Committee on Cancer stage), and treatment-related (induction chemotherapy, maximum p...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Donghyun Kim Yongkan Ki Wontaek Kim Dahl Park Jihyeon Joo Hosang Jeon Kyeonghyo Lee Jiho Nam Source Type: research

Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility?
Tumori. 2021 Nov 22:3008916211061604. doi: 10.1177/03008916211061604. Online ahead of print.ABSTRACTIn urothelial cancer of the bladder, the introduction of immunotherapy with immune checkpoint inhibitors represents progress in the management of the disease's early and advanced stages. In particular, recent studies have implemented these drugs in the neoadjuvant and adjuvant phases to treat muscle-invasive bladder cancer. In some studies, patients received neoadjuvant immune checkpoint inhibitors alone (PURE and ABACUS) to treat muscle invasive bladder cancer, whereas other studies provided this therapy to cisplatin-inelig...
Source: Tumori - November 22, 2021 Category: Cancer & Oncology Authors: Fausto Petrelli Gianluca Perego Ivano Vavassori Andrea Luciani Source Type: research

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report and review of the literature
We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.PMID:34761706 | DOI:10.1177/03008916211059230 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Fabio Turco Marcello Tucci Rosario Francesco Di Stefano Alessandro Samuelly Maristella Bungaro Enrico Bollito Giorgio Vittorio Scagliotti Consuelo Buttigliero Source Type: research

Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families
CONCLUSIONS: Among our patients, three developed tumors most frequently associated with DICER1 syndrome (i.e. pleuropulmonary blastoma, nephroblastoma, and Sertoli-Leydig cell tumor). One developed a peculiar sarcoma of the spinal cord not previously described in DICER1 syndrome. Genetic testing in relatives highlighted the paternal origin and reduced penetrance in all families, with thyroid benign lesions as the most common features in otherwise unaffected individuals.PMID:34761719 | DOI:10.1177/03008916211058788 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Jacopo Azzollini Andrea Ferrari Alessandra Stracuzzi Stefano Chiaravalli Monica Terenziani Filippo Spreafico Maurizia Grasso Paola Collini Valeria Pensotti Maura Massimino Eloisa Arbustini Siranoush Manoukian Source Type: research

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report and review of the literature
We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.PMID:34761706 | DOI:10.1177/03008916211059230 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Fabio Turco Marcello Tucci Rosario Francesco Di Stefano Alessandro Samuelly Maristella Bungaro Enrico Bollito Giorgio Vittorio Scagliotti Consuelo Buttigliero Source Type: research

Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families
CONCLUSIONS: Among our patients, three developed tumors most frequently associated with DICER1 syndrome (i.e. pleuropulmonary blastoma, nephroblastoma, and Sertoli-Leydig cell tumor). One developed a peculiar sarcoma of the spinal cord not previously described in DICER1 syndrome. Genetic testing in relatives highlighted the paternal origin and reduced penetrance in all families, with thyroid benign lesions as the most common features in otherwise unaffected individuals.PMID:34761719 | DOI:10.1177/03008916211058788 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Jacopo Azzollini Andrea Ferrari Alessandra Stracuzzi Stefano Chiaravalli Monica Terenziani Filippo Spreafico Maurizia Grasso Paola Collini Valeria Pensotti Maura Massimino Eloisa Arbustini Siranoush Manoukian Source Type: research

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report and review of the literature
We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.PMID:34761706 | DOI:10.1177/03008916211059230 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Fabio Turco Marcello Tucci Rosario Francesco Di Stefano Alessandro Samuelly Maristella Bungaro Enrico Bollito Giorgio Vittorio Scagliotti Consuelo Buttigliero Source Type: research

Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families
CONCLUSIONS: Among our patients, three developed tumors most frequently associated with DICER1 syndrome (i.e. pleuropulmonary blastoma, nephroblastoma, and Sertoli-Leydig cell tumor). One developed a peculiar sarcoma of the spinal cord not previously described in DICER1 syndrome. Genetic testing in relatives highlighted the paternal origin and reduced penetrance in all families, with thyroid benign lesions as the most common features in otherwise unaffected individuals.PMID:34761719 | DOI:10.1177/03008916211058788 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Jacopo Azzollini Andrea Ferrari Alessandra Stracuzzi Stefano Chiaravalli Monica Terenziani Filippo Spreafico Maurizia Grasso Paola Collini Valeria Pensotti Maura Massimino Eloisa Arbustini Siranoush Manoukian Source Type: research

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report and review of the literature
We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.PMID:34761706 | DOI:10.1177/03008916211059230 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Fabio Turco Marcello Tucci Rosario Francesco Di Stefano Alessandro Samuelly Maristella Bungaro Enrico Bollito Giorgio Vittorio Scagliotti Consuelo Buttigliero Source Type: research

Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families
CONCLUSIONS: Among our patients, three developed tumors most frequently associated with DICER1 syndrome (i.e. pleuropulmonary blastoma, nephroblastoma, and Sertoli-Leydig cell tumor). One developed a peculiar sarcoma of the spinal cord not previously described in DICER1 syndrome. Genetic testing in relatives highlighted the paternal origin and reduced penetrance in all families, with thyroid benign lesions as the most common features in otherwise unaffected individuals.PMID:34761719 | DOI:10.1177/03008916211058788 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Jacopo Azzollini Andrea Ferrari Alessandra Stracuzzi Stefano Chiaravalli Monica Terenziani Filippo Spreafico Maurizia Grasso Paola Collini Valeria Pensotti Maura Massimino Eloisa Arbustini Siranoush Manoukian Source Type: research

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report and review of the literature
We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.PMID:34761706 | DOI:10.1177/03008916211059230 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Fabio Turco Marcello Tucci Rosario Francesco Di Stefano Alessandro Samuelly Maristella Bungaro Enrico Bollito Giorgio Vittorio Scagliotti Consuelo Buttigliero Source Type: research

Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families
CONCLUSIONS: Among our patients, three developed tumors most frequently associated with DICER1 syndrome (i.e. pleuropulmonary blastoma, nephroblastoma, and Sertoli-Leydig cell tumor). One developed a peculiar sarcoma of the spinal cord not previously described in DICER1 syndrome. Genetic testing in relatives highlighted the paternal origin and reduced penetrance in all families, with thyroid benign lesions as the most common features in otherwise unaffected individuals.PMID:34761719 | DOI:10.1177/03008916211058788 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Jacopo Azzollini Andrea Ferrari Alessandra Stracuzzi Stefano Chiaravalli Monica Terenziani Filippo Spreafico Maurizia Grasso Paola Collini Valeria Pensotti Maura Massimino Eloisa Arbustini Siranoush Manoukian Source Type: research

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report and review of the literature
We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.PMID:34761706 | DOI:10.1177/03008916211059230 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Fabio Turco Marcello Tucci Rosario Francesco Di Stefano Alessandro Samuelly Maristella Bungaro Enrico Bollito Giorgio Vittorio Scagliotti Consuelo Buttigliero Source Type: research

Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families
CONCLUSIONS: Among our patients, three developed tumors most frequently associated with DICER1 syndrome (i.e. pleuropulmonary blastoma, nephroblastoma, and Sertoli-Leydig cell tumor). One developed a peculiar sarcoma of the spinal cord not previously described in DICER1 syndrome. Genetic testing in relatives highlighted the paternal origin and reduced penetrance in all families, with thyroid benign lesions as the most common features in otherwise unaffected individuals.PMID:34761719 | DOI:10.1177/03008916211058788 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Jacopo Azzollini Andrea Ferrari Alessandra Stracuzzi Stefano Chiaravalli Monica Terenziani Filippo Spreafico Maurizia Grasso Paola Collini Valeria Pensotti Maura Massimino Eloisa Arbustini Siranoush Manoukian Source Type: research

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report and review of the literature
We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.PMID:34761706 | DOI:10.1177/03008916211059230 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Fabio Turco Marcello Tucci Rosario Francesco Di Stefano Alessandro Samuelly Maristella Bungaro Enrico Bollito Giorgio Vittorio Scagliotti Consuelo Buttigliero Source Type: research

Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families
CONCLUSIONS: Among our patients, three developed tumors most frequently associated with DICER1 syndrome (i.e. pleuropulmonary blastoma, nephroblastoma, and Sertoli-Leydig cell tumor). One developed a peculiar sarcoma of the spinal cord not previously described in DICER1 syndrome. Genetic testing in relatives highlighted the paternal origin and reduced penetrance in all families, with thyroid benign lesions as the most common features in otherwise unaffected individuals.PMID:34761719 | DOI:10.1177/03008916211058788 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Jacopo Azzollini Andrea Ferrari Alessandra Stracuzzi Stefano Chiaravalli Monica Terenziani Filippo Spreafico Maurizia Grasso Paola Collini Valeria Pensotti Maura Massimino Eloisa Arbustini Siranoush Manoukian Source Type: research

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report and review of the literature
We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.PMID:34761706 | DOI:10.1177/03008916211059230 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Fabio Turco Marcello Tucci Rosario Francesco Di Stefano Alessandro Samuelly Maristella Bungaro Enrico Bollito Giorgio Vittorio Scagliotti Consuelo Buttigliero Source Type: research

Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families
CONCLUSIONS: Among our patients, three developed tumors most frequently associated with DICER1 syndrome (i.e. pleuropulmonary blastoma, nephroblastoma, and Sertoli-Leydig cell tumor). One developed a peculiar sarcoma of the spinal cord not previously described in DICER1 syndrome. Genetic testing in relatives highlighted the paternal origin and reduced penetrance in all families, with thyroid benign lesions as the most common features in otherwise unaffected individuals.PMID:34761719 | DOI:10.1177/03008916211058788 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Jacopo Azzollini Andrea Ferrari Alessandra Stracuzzi Stefano Chiaravalli Monica Terenziani Filippo Spreafico Maurizia Grasso Paola Collini Valeria Pensotti Maura Massimino Eloisa Arbustini Siranoush Manoukian Source Type: research

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report and review of the literature
We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.PMID:34761706 | DOI:10.1177/03008916211059230 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Fabio Turco Marcello Tucci Rosario Francesco Di Stefano Alessandro Samuelly Maristella Bungaro Enrico Bollito Giorgio Vittorio Scagliotti Consuelo Buttigliero Source Type: research

Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families
CONCLUSIONS: Among our patients, three developed tumors most frequently associated with DICER1 syndrome (i.e. pleuropulmonary blastoma, nephroblastoma, and Sertoli-Leydig cell tumor). One developed a peculiar sarcoma of the spinal cord not previously described in DICER1 syndrome. Genetic testing in relatives highlighted the paternal origin and reduced penetrance in all families, with thyroid benign lesions as the most common features in otherwise unaffected individuals.PMID:34761719 | DOI:10.1177/03008916211058788 (Source: Tumori)
Source: Tumori - November 11, 2021 Category: Cancer & Oncology Authors: Jacopo Azzollini Andrea Ferrari Alessandra Stracuzzi Stefano Chiaravalli Monica Terenziani Filippo Spreafico Maurizia Grasso Paola Collini Valeria Pensotti Maura Massimino Eloisa Arbustini Siranoush Manoukian Source Type: research

Carcinomatosis under control by osimertinib in < em > EGFR < /em > and < em > TP53 < /em > mutated lung adenocarcinoma
CONCLUSIONS: First-line treatment with osimertinib can be safe and effective in EGFR-mutated NSCLC even in presence of multiple negative predictive factors (poor Performance Status, diffuse leptomeningeal involvement, TP53 comutation), suggesting that deferring local treatments can be feasible in this setting, allowing the patient to maintain a good quality of life.PMID:34727807 | DOI:10.1177/03008916211052330 (Source: Tumori)
Source: Tumori - November 3, 2021 Category: Cancer & Oncology Authors: Leonardo Provenzano Valeria Cuccarini Marco Platania Luca Canziani Andrea Spagnoletti Fabio M Doniselli Marica Eoli Arsela Prelaj Elena Anghileri Source Type: research

Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy: oncologic outcomes and prognostic factors
CONCLUSION: In treatment of vaginal cancer, high-dose RT in combination with brachytherapy is well tolerated and results in effective local control rates, which significantly improve with an EQD2(α/β=10) ⩾65 Gy. Multivariate analyses revealed concomitant chemotherapy was a positive prognostic factor for overall and progression-free survival.PMID:34724840 | DOI:10.1177/03008916211056369 (Source: Tumori)
Source: Tumori - November 2, 2021 Category: Cancer & Oncology Authors: Eva Meixner Nathalie Arians Nina Bougatf Line Hoeltgen Laila K önig Kristin Lang Christoph Domschke Markus Wallwiener Jonathan W Lischalk Felix K F Kommoss J ürgen Debus Juliane H örner-Rieber Source Type: research

Use of PEAK PlasmaBlade in implant-based breast reconstruction and radiotherapy: new strategy to reduce complications
Tumori. 2021 Oct 31:3008916211056072. doi: 10.1177/03008916211056072. Online ahead of print.ABSTRACTBACKGROUND: Implant-based breast reconstruction in the setting of radiotherapy often leads to higher complications rates (mainly capsular contracture and wound dehiscence) and poor cosmetic outcomes. We hypothesized that the combination of pulsed-electron avalanche knife (PEAK) PlasmaBlade (a pulsed radiofrequency electrosurgery) and acellular dermal matrix Veritas® in postmastectomy radiotherapy implant-based breast reconstruction could result in lower complications rate, better reconstructive results, and patient satis...
Source: Tumori - November 1, 2021 Category: Cancer & Oncology Authors: Laura Sala Stefano Bonomi Alessandra Fabbri Chiara Maura Ciniselli Annalisa Bardelli Paolo Verderio Giancarlo Pruneri Umberto Cortinovis Source Type: research

Long survival of a young patient with Xp11.2 translocation metastatic clear cell renal carcinoma: case report and review of the literature
CONCLUSIONS: The patient had an overall survival (OS) of 51 months, which is much higher than that reported in literature data. Unfortunately, the biology of Xp11.2 translocation RCC and its therapeutic management are still unclear.PMID:34696653 | DOI:10.1177/03008916211049275 (Source: Tumori)
Source: Tumori - October 26, 2021 Category: Cancer & Oncology Authors: Stefania Pipitone Maria Giuseppa Vitale Cinzia Baldessari Massimo Dominici Roberto Sabbatini Source Type: research